End to end Signal Management Services with advanced Signal Detection Analytics
Signal detection is a key component of pharmacovigilance and the whole process of risk/benefit evaluation depends on the effectiveness of signal management system.
European Medical Agency (EMA) has launched new EudraVigilance system on 22 Nov 2017 with access to all marketing authorization holders (MAHs)/License holders for monitoring of validated signals from “list of medicinal products underadditional monitoring” and inform the respective national competent authority of member state as per regulation No 520/2012 (article 18).
Based on this regulatory guidance documents (GVP module IX) have been revised regarding process of monitoring and reporting of safety signals.
With the ever increasing scrutiny by regulatory authorities and public, MAHs need to strengthen their signal management systems. National Competent Authorities can request these documentations at any time which requires the proactive safety evaluation and reporting processes to be working efficiently and increased transparency through communication of information/evidence.
iSafety Technology integrated Proactive Signal Management System
iSignalProTM provides MAH and regulatory authorities with a clear Signal Pathway from Signal Identification, Signal Monitoring, Signal Review to Signal Closure/Recommendations and Safety Updates.
>> identifies new risks or a change in risk associated with an active substance or a medicinal product.
>> applies advanced data mining techniques to a variety of spontaneous reporting databases including EudraVigilance to identify potential, validated safety signals.
>> covers all steps from detecting signals, through their validation and confirmation, analysis through prioritization and assessment to recommending action.
iSignalProTM mitigates the challenges, often MAH face to remain compliant with their signal management processes, including;
iSignalProTM functions on a global platform and provides MAHs/companies with:
iSafety 2019 © All Rights Reserved.